Test drug to prevent clots in mild to moderate liver disease
Part of Digestive system clinical trials.
This Phase 2 study tests a blood-thinner called a DOAC in people with previously diagnosed mild or moderate liver cirrhosis (Child A or B). It may help doctors understand whether the medicine is safe and effective in this group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been told you have liver cirrhosis classified as Child A or Child B
- You can read and sign the consent form to join the study
- You are not pregnant
- Your esophagus bleeding risk must not be too high (no varices higher than grade 1, and no red signs)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early study tests whether the blood thinner pills rivaroxaban and apixaban can be used safely in people with liver cirrhosis that is not too severe. It may help doctors understand the safest way to prevent or treat blood clots in this group.
This trial tests whether the blood thinner apixaban can help prevent early-stage cirrhosis from worsening. You may be eligible if you have compensated (stable) cirrhosis due to alcohol and have signs of portal hypertension.
This trial tests whether a pill (dabigatran) or a daily injection (enoxaparin) is better at preventing new blood clots in the liver vein for people with cirrhosis. Both are blood thinners, and the study wants to see which one is safer and more effective.
This Phase 4 study looks at how clotting measurements relate to bleeding risk in people with liver cirrhosis who need a planned liver procedure. The study may help doctors understand what coagulation results mean when doing these procedures safely.
This study tests whether a blood thinner called apixaban can safely prevent dangerous bleeding in people with cirrhosis (liver scarring) who have portal hypertension (high blood pressure in veins leading to the liver). The goal is to see if it reduces bleeding risk without causing excessive bleeding.
This trial tests a new oral blood thinner to prevent another bleeding episode in people with liver cirrhosis who have already had variceal bleeding and also have a clot in the portal vein. The goal is to see if it can safely reduce the risk of rebleeding.
Hear when a new Liver Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.